Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children (Abilify)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00468130|
Recruitment Status : Completed
First Posted : May 2, 2007
Last Update Posted : October 2, 2014
Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale.
(2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity.
The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.
|Condition or disease||Intervention/treatment|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children|
|Study Start Date :||May 2006|
|Primary Completion Date :||November 2009|
|Study Completion Date :||November 2009|
Subjects in the experimental group will receive Aripiprazole
Subjects under 40 kg will be started on 2.5mg per day of aripiprazole or placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Other Name: Abilify
Placebo Comparator: Placebo
Subjects in the control group will receive placebo
- Clinical Global Impression Improvement (CGI-AD) [ Time Frame: Administered weekly ]
- Aberrant Behavior Checklist [ Time Frame: Administered weekly ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00468130
|United States, New Jersey|
|Department of Child and Adolescent Psychiatry, University Behavioral Health Care Building|
|Piscataway, New Jersey, United States, 08854|
|Principal Investigator:||Sherie L. Novotny, MD||Child and Adolescent Psychiatry, UMDNJ|